Diltiazem HCl Injectable Drug Recalled for Sterility Assurance Failure
Nephron Sterile Compounding Center is recalling Diltiazem HCl injectable due to lack of sterility assurance. The FDA Class II recall affects 4,743 bottles distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for an injectable medication. No illnesses, injuries, or deaths are reported in the source. Per the severity rubric, this scores 3 (High) as a risk-of-harm product (injectable with potential for serious infections if contaminated) where injury has not yet been reported. Class II status without reported harm does not meet the threshold for Score 4 (Severe).
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (125 mL single-dose bottles). The affected lot is DS2053, expiration date February 27, 2023, with approximately 4,743 bottles distributed nationwide.
The FDA determined that this lot lacks assurance of sterility. Sterility is critical for injectable medications to prevent potentially serious infections.
Healthcare facilities and pharmacies that received product from lot DS2053 should identify any remaining inventory and follow appropriate quarantine procedures. Patients or individuals who received injections from this batch should consult their healthcare provider.
The recalled product
- Product
- Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose Container bottle, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-997-15.
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable / Intravenous
- Affected units
- 4,743
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: DS2053
- Exp. 2/27/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 8 recalled by Nephron Sterile Compounding Center LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 8 products in this recall →Related recalls
Same manufacturer · Nephron Sterile Compounding Center LLC
See all →- HighSodium Chloride Injection Recalled for Potential Sterility Compromise
FDA (Drugs) · 2025-03-19
- HighFDA Recalls Norepinephrine Injection Due to Sterility Concerns
FDA (Drugs) · 2023-03-08
- HighNephron Phenylephrine HCl Injection Recalled for Sterility Assurance
FDA (Drugs) · 2023-03-08
- HighPhenylephrine HCl Injection Recalled for Sterility Assurance Deficiency
FDA (Drugs) · 2023-03-08
- HighPhenylephrine injection lacks sterility assurance; FDA recalls vials
FDA (Drugs) · 2023-03-08
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22